110 related articles for article (PubMed ID: 23980682)
1. Anticancer mechanism of apigenin and the implications of GLUT-1 expression in head and neck cancers.
Bao YY; Zhou SH; Fan J; Wang QY
Future Oncol; 2013 Sep; 9(9):1353-64. PubMed ID: 23980682
[TBL] [Abstract][Full Text] [Related]
2. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells.
Melstrom LG; Salabat MR; Ding XZ; Milam BM; Strouch M; Pelling JC; Bentrem DJ
Pancreas; 2008 Nov; 37(4):426-31. PubMed ID: 18953257
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo.
Bao YY; Zhou SH; Lu ZJ; Fan J; Huang YP
Oncol Rep; 2015 Oct; 34(4):1805-14. PubMed ID: 26238658
[TBL] [Abstract][Full Text] [Related]
4. Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1.
Fang J; Bao YY; Zhou SH; Fan J
Mol Med Rep; 2015 Nov; 12(5):6461-6. PubMed ID: 26300442
[TBL] [Abstract][Full Text] [Related]
5. Expression of glucose transporter-1 and -3 in the head and neck carcinoma--the correlation of the expression with the biological behaviors.
Zhou S; Wang S; Wu Q; Fan J; Wang Q
ORL J Otorhinolaryngol Relat Spec; 2008; 70(3):189-94. PubMed ID: 18401196
[TBL] [Abstract][Full Text] [Related]
6. [Expression of Glut-1 and Glut-3 in the head and neck squamous carcinoma].
Zhou SH; Wang SQ; Wu QL
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Aug; 41(8):623-5. PubMed ID: 17039809
[No Abstract] [Full Text] [Related]
7. Diagnostic value of GLUT-1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine-needle aspiration biopsy material.
Weiner MF; Miranda RN; Bardales RH; Mukunyadzi P; Baker SJ; Korourian S; De Las Casas LE
Diagn Cytopathol; 2004 Nov; 31(5):294-9. PubMed ID: 15468132
[TBL] [Abstract][Full Text] [Related]
8. Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study.
Xu YY; Wu TT; Zhou SH; Bao YY; Wang QY; Fan J; Huang YP
Int J Clin Exp Pathol; 2014; 7(7):3938-47. PubMed ID: 25120770
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress.
Lee YM; Lee G; Oh TI; Kim BM; Shim DW; Lee KH; Kim YJ; Lim BO; Lim JH
Int J Oncol; 2016 Jan; 48(1):399-408. PubMed ID: 26573871
[TBL] [Abstract][Full Text] [Related]
10. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor.
Shin HC; Song DW; Baek WK; Lee SR; Kwon TK; Lee J; Park SH; Jang BC; Park JW
Chemotherapy; 2009; 55(5):353-62. PubMed ID: 19657189
[TBL] [Abstract][Full Text] [Related]
12. [Chemosensitivity testing of anticancer agents in head and neck tumors. I: Comparison between head and neck squamous cell cancers and thyroid cancers].
Nakashima T; Tomita K; Kuratomi Y; Maehara Y; Kohnoe S
Gan To Kagaku Ryoho; 1990 Jan; 17(1):79-84. PubMed ID: 2297240
[TBL] [Abstract][Full Text] [Related]
13. Insights into novel anticancer applications for apigenin.
Kowalczyk A; Bodalska A; Miranowicz M; Karłowicz-Bodalska K
Adv Clin Exp Med; 2017 Oct; 26(7):1143-1146. PubMed ID: 29211364
[TBL] [Abstract][Full Text] [Related]
14. Effect on the expression of MMP-2, MT-MMP in laryngeal carcinoma Hep-2 cell line by antisense glucose transporter-1.
Xu YY; Bao YY; Zhou SH; Fan J
Arch Med Res; 2012 Jul; 43(5):395-401. PubMed ID: 22835601
[TBL] [Abstract][Full Text] [Related]
15. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer.
Liu LZ; Fang J; Zhou Q; Hu X; Shi X; Jiang BH
Mol Pharmacol; 2005 Sep; 68(3):635-43. PubMed ID: 15947208
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-2 as a target for head and neck cancer therapy.
Chien MH; Lin CW; Cheng CW; Wen YC; Yang SF
Expert Opin Ther Targets; 2013 Feb; 17(2):203-16. PubMed ID: 23252422
[TBL] [Abstract][Full Text] [Related]
17. Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines.
Riedel F; Götte K; Goessler U; Sadick H; Hörmann K
Anticancer Res; 2004; 24(4):2179-83. PubMed ID: 15330158
[TBL] [Abstract][Full Text] [Related]
18. Genistein elicits pleiotropic molecular effects on head and neck cancer cells.
Alhasan SA; Aranha O; Sarkar FH
Clin Cancer Res; 2001 Dec; 7(12):4174-81. PubMed ID: 11751518
[TBL] [Abstract][Full Text] [Related]
19. Apigenin: A dietary flavonoid with diverse anticancer properties.
Madunić J; Madunić IV; Gajski G; Popić J; Garaj-Vrhovac V
Cancer Lett; 2018 Jan; 413():11-22. PubMed ID: 29097249
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells.
Mirzoeva S; Kim ND; Chiu K; Franzen CA; Bergan RC; Pelling JC
Mol Carcinog; 2008 Sep; 47(9):686-700. PubMed ID: 18240292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
